
| Pair Name | Oxidized tea polyphenol, Nimotuzumab | |||
| Partner Name | Oxidized tea polyphenol | |||
| Disease Info | [ICD-11: 2C25.Z] | Lung cancer | Investigative | |
| Gene Regulation | Down-regulation | Expression | EGFR | hsa1956 |
| Down-regulation | Phosphorylation | MAPK1 | hsa5594 | |
| Down-regulation | Phosphorylation | AKT1 | hsa207 | |
| Down-regulation | Phosphorylation | STAT3 | hsa6774 | |
| Down-regulation | Phosphorylation | GSK3B | hsa2932 | |
| Up-regulation | Expression | BAX | hsa581 | |
| Down-regulation | Expression | BCL2 | hsa596 | |
| Up-regulation | Cleavage | PARP1 | hsa142 | |
| In Vitro Model | NCI-H1781 | Minimally invasive lung adenocarcinoma | Homo sapiens (Human) | CVCL_1494 |
| In Vivo Model | NCI-H1781 cells (5 × 106 cells per mice) were subcutaneously injected into the flank of each nu/nu mice. 3 days later, the mice were treated by intraperitoneal injection OTP-3 and nimotuzumab (three times per week) for the indicated period. | |||
| Result | OTP-3 can also serve as an effective therapeutic agent in NSCLC where it can augment the effects of nimotuzumab, a valuable property for combination agents. | |||